Browse the evidence

Electronic health record (EHR) data from the one-year period prior to initiating anti-obesity medication (AOM) contains sufficient multidimensional clinical signals to identify distinct obesity subtypes (clusters) with unique physiological profiles, enabling precision medicine approaches that outperform traditional BMI-based classifications.

If you are considering obesity medication, ask your doctor about 'deep phenotyping.' This means using your full medical history (labs, vitals, diagnoses) from the past year to group you into a specific 'obesity subtype.' This helps predict which medication will work best for you, rather than just using your BMI. It reduces the guesswork in choosing between different drugs like GLP-1 agonists or others.

Protein supplementation during endurance training significantly improves time to exhaustion (TTE) with a moderate effect size, despite having no significant effect on maximal oxygen uptake (VO2max) or body composition in the general population.

If you are doing endurance training, adding protein supplements will likely help you exercise for a longer time before exhaustion. However, do not expect this to significantly change your body weight, body fat, or maximum oxygen capacity (VO2max) unless you are currently untrained. Focus on the performance duration benefit rather than body composition changes.

Untrained individuals may experience greater improvements in maximal oxygen uptake (VO2max) from protein supplementation during endurance training compared to trained individuals.

If you are new to endurance training, adding protein supplements might help slightly improve your maximum oxygen uptake (VO2max). This benefit is likely not present if you are already a trained endurance athlete.

Dumbbell and cable lateral raises produce equivalent lateral deltoid hypertrophy when shoulder abduction/adduction range of motion is standardized and matched between conditions.

You can use either dumbbells or cables for lateral raises to build your side delts. The key is to match the range of motion (lifting your arm to about 90 degrees) and train to failure for 5 sets, twice a week. Don't worry about which machine is 'better' mechanically; just pick the one you prefer and stick with it.

Front-of-pack labeling (FOPL) and sugar-sweetened beverage (SSB) taxes are cost-effective population-level primary prevention strategies that reduce consumption, though their effectiveness varies by socioeconomic status and literacy.

Support policies like sugar taxes and clear food labeling. These are proven to reduce sugary drink consumption and encourage companies to make healthier products. While they may not solve obesity alone, they are a cost-effective way to improve population health.

Bariatric surgery provides superior, durable weight loss and metabolic improvement compared to non-surgical interventions, including pharmacotherapy.

If you have severe obesity (BMI ≥40, or ≥35 with health issues) and lifestyle changes haven't worked, bariatric surgery is the most effective long-term solution for weight loss and metabolic health. While it has higher upfront costs and risks, it is more cost-effective over time than lifelong medication. Consult a specialist to see if you qualify.

Metformin, alpha-lipoic acid (ALA), and GLP-1 receptor agonists are effective, complementary pharmacological interventions for managing metabolic syndrome, with metformin serving as the universal first-line treatment due to its safety, low cost, and wide availability.

For patients with Metabolic Syndrome, especially in crisis or resource-limited settings, start with metformin as the primary treatment due to its proven safety, low cost, and wide availability. Add alpha-lipoic acid (ALA) to target oxidative stress and insulin sensitivity, and consider GLP-1 agonists if cardiovascular risk is high and resources allow. Simplify regimens and use telemedicine to support adherence, as stress and disruption are major barriers to care.

The MicroSimulation Core Obesity Model (MS-COM) accurately predicts cardiovascular and mortality outcomes in adults with overweight or obesity, including those with normoglycemia, prediabetes, or type 2 diabetes, supporting its use for evaluating obesity management interventions.

For policymakers and health technology assessment bodies, the MS-COM model provides a reliable tool to evaluate the cost-effectiveness of obesity interventions (like semaglutide 2.4 mg) by accurately predicting long-term cardiovascular and mortality risks in overweight and obese adults, including those with diabetes.

Tirzepatide treatment for obesity is associated with a very low incidence of macronutrient malnutrition and vitamin deficiency adverse events, with fewer than 1% of patients discontinuing treatment due to nutritional status concerns.

If you are taking tirzepatide for obesity, the risk of developing serious nutritional deficiencies or malnutrition is very low, especially if you follow the recommended dietary counseling. The study showed that fewer than 1% of patients had adverse events related to malnutrition. To stay healthy, focus on the recommended diet (high protein, balanced macros) and attend your lifestyle counseling sessions.

Achieving optimal control of multiple risk factors (lifestyle and metabolic) in type 2 diabetes can restore life expectancy to levels comparable to individuals without diabetes.

If you have type 2 diabetes, focus on controlling your risk factors (blood sugar, blood pressure, lipids, smoking, diet, and exercise). Doing so can add 6-9 years to your life compared to poor management and may even bring your life expectancy in line with someone who doesn't have diabetes.

A healthy lifestyle can compensate for suboptimal metabolic control to provide longevity benefits in type 2 diabetes.

Even if your blood sugar or other metabolic numbers aren't perfect, maintaining a healthy lifestyle (not smoking, regular exercise, healthy diet) can still add 1.5-3.4 years to your life compared to someone who has perfect numbers but an unhealthy lifestyle.

Transitioning from obesity to non-obesity, transitioning from non-obesity to obesity, or maintaining stable obesity is associated with an elevated risk of chronic kidney disease (CKD) compared to maintaining stable non-obesity.

Maintaining a stable, non-obese weight is the most protective strategy for kidney health. Both gaining weight (if you are not obese) and losing weight (if you are obese) carry higher risks than staying stable. If you are obese, aim for gradual, sustainable weight management rather than rapid loss, as rapid loss may harm kidney function. Avoid weight cycling.

Extreme weight gain (≥20 kg) and substantial weight loss (>2.5 kg) are associated with increased CKD risk, forming a J-shaped or U-shaped relationship.

Avoid both extreme weight gain and substantial weight loss. Even small gains (≥2.5 kg) can increase kidney risk, especially in young adulthood. If you are obese, avoid rapid or substantial weight loss as it may also harm kidney function. Focus on stability.

The association between weight change patterns and CKD risk is stronger in individuals under 60 years of age at baseline compared to those 60 years or older.

If you are under 60, pay close attention to your weight stability. The risk to your kidneys from weight fluctuations is higher for you than for older adults. Prioritize maintaining a stable, healthy weight.

The mortality benefits of healthful plant-based diets are more pronounced in younger adults (<65 years) and men, while the risks of unhealthful plant-based diets are significantly stronger in individuals with obesity (BMI ≥ 25 kg/m²).

If you are under 65 or have obesity, paying close attention to the quality of your plant foods (choosing whole grains over refined ones) may offer you particularly strong protection against mortality. For older adults or those with normal BMI, the benefits still exist but may be less pronounced.

The primary sources of ultra-processed food energy intake vary by age group, with alcohol and grain-based products being major contributors across all groups, while legumes, milk, and dairy products become more significant contributors as UPF consumption increases and age rises.

Identify the specific ultra-processed foods that make up the bulk of your UPF intake. For many Koreans, this includes alcohol and grain-based products. For older adults, UPFs from legumes, milk, and dairy may also be significant contributors. Targeting these specific categories for reduction or substitution may be more effective than a blanket 'no UPF' rule.

Varying proximity-to-failure (progressively decreasing RIR from 4 to 1) does not enhance short-term muscle strength or hypertrophy compared to consistently training at 1 RIR in resistance-trained individuals.

If you are an experienced lifter, you do not need to vary your proximity to failure week-to-week to get stronger or bigger. Training consistently at 1 Repetition in Reserve (RIR 1) produces the same results as a program that starts easy (RIR 4) and gets harder (RIR 1). However, the varying approach results in lower perceived exertion (RPE) during the easier weeks, which may make the training feel less stressful without sacrificing gains.

In patients with heart failure and reduced ejection fraction (HFrEF), a BMI greater than 27 kg/m² is associated with significantly higher risks of cardiovascular mortality, heart failure hospitalization, and composite adverse outcomes compared to a BMI of 24–27 kg/m².

If you have heart failure with reduced ejection fraction, maintaining a BMI between 24 and 27 kg/m² is associated with better survival and fewer hospitalizations than having a BMI over 27. This is especially true if your heart failure is caused by coronary artery disease (ischemic). You should discuss weight management strategies with your cardiologist, as higher BMI may increase your risk of cardiovascular death and hospitalization.

Incretin-based therapies (GLP-1RA and dual agonists) cause a mild absolute decrease in skeletal muscle mass and strength, but this is offset by a disproportionately larger loss of fat and liver mass, resulting in improved relative muscle-to-body-weight ratios and preserved or enhanced physical function.

If you are using incretin-based medications for weight loss, expect some loss of absolute muscle mass, but do not panic about 'wasting.' The medication preferentially burns fat and liver fat, which improves your muscle-to-weight ratio. Your strength and endurance often improve because you are carrying less weight. To maximize muscle retention, prioritize resistance training and adequate protein intake, as the drug itself does not protect muscle mass but does not disproportionately destroy it either.

Tirzepatide treatment yields greater improvements in physical function for patients with lower baseline physical function scores compared to those with higher baseline scores, despite similar magnitude of weight loss across all baseline levels.

If you have obesity and struggle with physical function (e.g., difficulty walking, climbing stairs), starting tirzepatide is highly recommended. You will likely lose weight just as effectively as someone who is more active, and you may experience the most dramatic improvements in your daily physical capabilities. Do not let current mobility issues stop you from seeking treatment.

Dietary interventions alone are insufficient for long-term obesity management due to biological resistance mechanisms that promote weight regain, necessitating a multi-modal approach including physical activity, behavioral therapy, pharmacotherapy, or surgery.

Stop looking for a single 'magic' diet that cures obesity. Sustainable weight management requires a combination of safe nutrition, regular physical activity, and behavioral support. If lifestyle changes are insufficient, consult a doctor about pharmacotherapy or surgery. Focus on long-term health improvements (blood pressure, glucose) rather than just the number on the scale, and be aware that biological mechanisms will fight weight loss, so ongoing maintenance strategies are essential.

In individuals with obesity and multiple long-term conditions (MLTCs), BMI reductions of ≥7% are associated with a lower risk of developing new obesity-related complications (ORCs) and reduced polypharmacy compared to stable BMI, whereas both significant weight loss and weight gain are associated with increased hazards for mental-health conditions, hospitalization, and mortality.

For people with obesity and multiple chronic conditions, losing weight (≥7%) can help prevent new diseases and reduce the number of medications. However, this population also faces higher risks of mental health issues, hospitalization, and mortality with both weight loss and gain compared to maintaining a stable weight. Treatment should be personalized, focusing on overall health outcomes rather than weight change alone.

Bariatric surgery remains the most efficacious treatment for obesity, producing sustained weight loss of approximately 20% or higher and superior metabolic improvements compared to pharmacotherapy alone.

If you have severe obesity, bariatric surgery is currently the most effective medical intervention for achieving significant, sustained weight loss and reversing metabolic diseases like type 2 diabetes. While it is invasive, it is considered safe and offers better long-term outcomes than medication alone for many patients.

Combining CPAP therapy with weight loss (via pharmacotherapy or lifestyle) yields greater improvements in cardiovascular risk markers than treating either condition alone.

If you have sleep apnea and are overweight, don't just focus on one. Using CPAP while also working to lose weight (through diet, exercise, or medication) provides the best protection for your heart and blood pressure. Treating just one condition leaves you at higher risk.